BofA raises target for Eli Lilly and Co stock from USD 1,341.00 to USD 1,397.00

Published on 10/27/2026 at 18:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lilly reports third-quarter results on October 29, 2026. Eli Lilly and Co stock costs EUR 1,151.40 on October 27, 2026, plus 0.21 percent versus Xetra close.

Analyst view and earnings date

BofA lifted its Eli Lilly target from USD 1,341.00 to USD 1,397.00 on October 19, 2026.
Second-quarter 2026 revenue reached USD 23.0 billion, up 48.00 percent year over year.
Eli Lilly and Co stock costs EUR 1,151.40 at Lang & Schwarz on October 27, 2026 at 6:18 p.m. CEST, plus 0.21 percent versus the Xetra close of October 27, 2026.

Eli Lilly and Co., US5324571083, Illustration mit AI erstellt.

Bank of America raised its Eli Lilly and Co price target from USD 1,341.00 to USD 1,397.00 on October 19, 2026, while keeping a Buy rating, as Markets Insider reported. Eli Lilly and Co stock was trading at EUR 1,151.40 at Lang & Schwarz on October 27, 2026 at 6:18 p.m. CEST, plus 0.21 percent versus the Xetra close of October 27, 2026 at EUR 1,149.00.

Revenue sets a high bar

The company entered the next reporting date with substantial operating momentum. Second-quarter 2026 revenue was USD 23.0 billion, up 48.00 percent from the year-earlier period, according to Yahoo Finance. The same report cited full-year revenue guidance of USD 85.0 billion to USD 87.0 billion, while Goldman Sachs modeled USD 89.8 billion.

Stock stays below its high

The euro quotation remains EUR 23.40 below the 52-week high of EUR 1,175.80, based on the German quotation as of October 27, 2026. The 52-week low was EUR 697.70. The primary-market reference is the NYSE, where Eli Lilly closed at USD 1,279.14 on October 26, 2026.

Valuation meets an earnings date

The latest primary-market quotation carried a price-to-earnings ratio of 42.98 and a market capitalization of USD 1.2 trillion as of October 27, 2026. Eli Lilly will announce third-quarter 2026 results on October 29, 2026, according to its October 15 release, which also scheduled the call for 10:00 a.m. Eastern time. The date was confirmed by Eli Lilly and Company.

Comparison with peers

Eli Lilly and Co: plus 0.21 percent versus the Xetra close, price-to-earnings ratio 43.00, market capitalization USD 1.2 trillion.
Novo Nordisk (NYSE, USD): minus 1.01 percent, price-to-earnings ratio 9.91, market capitalization USD 171.0 billion.
Merck & Co. (NYSE, USD): plus 1.05 percent, price-to-earnings ratio 113.65, market capitalization USD 350.6 billion.

What comes before the results

The immediate calendar marker is October 29, 2026, when the company will publish its third-quarter figures. The combination of USD 23.0 billion in second-quarter revenue and a USD 85.0 billion to USD 87.0 billion full-year outlook leaves the next report as the next quantified test of demand.

Price and earnings outlook

Eli Lilly and Co stock was trading at EUR 1,151.40 at Lang & Schwarz on October 27, 2026 at 6:18 p.m. CEST, plus 0.21 percent versus the Xetra close of October 27, 2026 at EUR 1,149.00. On the NYSE, the stock closed at USD 1,279.14 on October 26, 2026. The further course of trading is shown by the continuously updated real-time quote of Eli Lilly and Co stock.